Latest & greatest articles for montelukast

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on montelukast or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on montelukast and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for montelukast

21. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review (PubMed)

Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review To systematically review the evidence for the medium to long term benefits and risks of montelukast as add-on therapy to inhaled corticosteroids (ICS) in comparison with placebo and active controls in mild to moderate asthma.Medline, Embase, Cochrane Register of Controlled Trials, reference lists of retrieved articles, clinical trial registries and study results (...) databases.Systematic review of randomised controlled trials (duration > or = 12 weeks) in adolescents and adults comparing montelukast/ICS versus ICS monotherapy or montelukast/ICS versus active control/ICS. Meta-analyses were conducted where feasible. The main focus was on clinical outcomes (eg, exacerbations). Adverse events were also assessed.13 studies meeting all of the inclusion criteria were identified: 7 studies, including constant or tapered doses of ICS, compared montelukast/ICS with ICS monotherapy. Six

Full Text available with Trip Pro

2008 EvidenceUpdates

22. Pretreatment with Albuterol versus Montelukast for Exercise-Induced Bronchospasm in Children (PubMed)

Pretreatment with Albuterol versus Montelukast for Exercise-Induced Bronchospasm in Children To compare pretreatment with albuterol versus montelukast added to the current asthma regimen for protection against exercise-induced bronchospasm in children with mild-to-moderate asthma, and to determine whether cysteinyl leukotriene (Cys-LT) concentrations measured in the exhaled breath condensate correlated with response to montelukast.Prospective, randomized, double-blind, double-dummy, crossover (...) study.Asthma clinic at a university-affiliated medical center.Eleven children aged 7-17 years with physician-diagnosed mild-to-moderate asthma for at least 6 months and with self-reported exercise-induced bronchospasm (defined as > or = 15% decrease in forced expiratory volume in 1 sec [FEV(1)] at screening and baseline visit).Patients were randomly assigned to receive 3-7 days of oral montelukast 5-10 mg/day or 2 puffs of an albuterol metered-dose inhaler just before an exercise challenge and then were

2008 EvidenceUpdates

23. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review

Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, Schneider A CRD summary The authors concluded that adding montelukast (...) to inhaled corticosteroids (ICS) improved control of mild to moderate asthma, and that salmeterol was at least as effective as montelukast as an add-on therapy, but that montelukast may be safer long term. These conclusions may require some caution in interpretation due to the scarcity of good quality data and heterogeneity between the studies. Authors' objectives To evaluate the medium to long-term use of montelukast as add-on therapy to inhaled corticosteroids (ICS) in adolescents and adults

2008 DARE.

24. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs

Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs O'Connor R D (...) ) and salmeterol (50 microg) administered twice daily from a single discus (FP-S); fluticasone propionate (FP; 100 microg); and montelukast (MO; 10 mg). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged 15 years or older with a diagnosis of asthma, as defined by the American Thoracic Society, for at least 6 months. Patients were required to demonstrate a pre-dose forced expiratory volume in one second (FEV1) of 50

2004 NHS Economic Evaluation Database.

25. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma O'Connor R D, Nelson H, Borker R, Emmett A, Jhingran P (...) administered via a single Diskus inhaler device twice daily. The other was an alternative strategy consisting of FP 100 microg twice daily via a Diskus inhaler plus oral montelukast (MON) 10 mg once daily. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged more than 15 years who had had asthma for at least 6 months and had been taking low-to-moderate doses of an ICS for at least 30 days before screening. At the time

2004 NHS Economic Evaluation Database.

26. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. (PubMed)

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasone alone. Design and setting A 52 week, two period, double blind, multicentre trial during which patients whose symptoms remained (...) uncontrolled by inhaled corticosteroids were randomised to add montelukast or salmeterol.Patients (15-72 years; n = 1490) had a clinical history of chronic asthma for > or = 1 year, a baseline forced expiratory volume in one second (FEV1) value 50-90% predicted, and a beta agonist improvement of > or = 12% in FEV1.The primary end point was the percentage of patients with at least one asthma exacerbation.20.1% of the patients in the group receiving montelukast and fluticasone had an asthma exacerbation

Full Text available with Trip Pro

2003 BMJ

27. A clinical review of montelukast in the treatment of seasonal allergic rhinitis

A clinical review of montelukast in the treatment of seasonal allergic rhinitis A clinical review of montelukast in the treatment of seasonal allergic rhinitis A clinical review of montelukast in the treatment of seasonal allergic rhinitis Gonyeau M J, Partisano A M CRD summary This review aimed to compare the efficacy of montelokast with current therapies for seasonal allergic rhinitis. The authors concluded that there was no evidence to support the use of montelokast (alone or in combination (...) with antihistamines) over intranasal corticosteroids. Limitations in the review methods and the reporting of included studies mean that these conclusions should be viewed with caution. Authors' objectives To assess the efficacy of montelukast in comparison with current therapies for seasonal allergic rhinitis. Searching MEDLINE and EMBASE were searched (1990 to week 8, 2003); the search terms were reported. Only studies published in the English language were included. Study selection Study designs of evaluations

2003 DARE.

28. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population

Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population Pathak D S, Davis E A, Stanford R H Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology was controller therapy for patients with asthma. The comparators were inhaled corticosteroids and leukotriene modifiers in real world clinical practice. The authors compared fluticasone propionate (44 or 110 microg) with oral zafirlukast (20 mg) and montelukast

2002 NHS Economic Evaluation Database.

29. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs

Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs Stempel D A, O'Donnell J C, Meyer J W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two alternative treatments for patients with moderate persistent asthma were examined. The treatments were inhaled corticosteroids (ICSs) used concurrently with salmeterol (ICS+SAL) or montelukast (ICS+MON). A third comparator, inhaled fluticasone propionate plus SAL (FP+SAL), was also considered. Type of intervention Treatment. Economic study

2002 NHS Economic Evaluation Database.

30. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P Record Status This is a critical (...) the Diskus device versus montelukast (MONT; 10 mg) once daily, for 12 weeks. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients suffering from asthma for at least 6 months, who had been treated with an oral or inhaled short-acting beta2-agonist on a scheduled, or as-needed basis for at least 6 weeks before screening. The patients were required to have a forced expiratory volume in 1 second (FEV1) of between 50 and 80

2002 NHS Economic Evaluation Database.

31. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. (PubMed)

Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. To determine the ability of montelukast, a leukotriene receptor antagonist, to allow tapering of inhaled corticosteroids in clinically stable asthmatic patients.Double blind, randomised, placebo controlled, parallel group study. After a single blind placebo run in period, during which (at most) two inhaled corticosteroids dose decreases (...) occurred, qualifying, clinically stable patients were allocated randomly to receive montelukast (10 mg tablet) or matching placebo once daily at bedtime for up to 12 weeks.23 academic asthma centres in United States, Canada, and Europe.226 clinically stable patients with chronic asthma receiving high doses of inhaled corticosteroids (113 randomised to montelukast and 113 to placebo).Every 2 weeks, the inhaled corticosteroids dose was tapered, maintained, or increased (rescue) based on a standardised

Full Text available with Trip Pro

1999 BMJ

32. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. (PubMed)

Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. Patients with mild asthma frequently have only exercise-induced bronchoconstriction, a symptom of inadequate control of asthma. We evaluated the ability of montelukast, a leukotriene-receptor antagonist, to protect such patients against exercise-induced bronchoconstriction.We randomly assigned 110 patients (age, 15 to 45 years) with mild asthma and a decrease in the forced (...) expiratory volume in one second (FEV1) of at least 20 percent after exercise on two occasions during a placebo run-in period to receive 10 mg of montelukast (54 patients) or placebo (56 patients) once daily at bedtime for 12 weeks in a double-blind study. Treatment was followed by a two-week, single-blind washout period during which all patients received placebo. Exercise challenges were performed at base line; 20 to 24 hours after dosing at weeks 4, 8, and 12; and at the end of the washout period

1998 NEJM

33. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. (PubMed)

Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. Leukotrienes are important mediators of asthma by causing bronchoconstriction, mucous secretion, and increased vascular permeability. Studies using compounds that block leukotrienes have demonstrated improvement in asthma control in adults and adolescents, but children younger than 12 years, for whom asthma is the most common chronic disease, have not been (...) studied.To determine the clinical effect of montelukast, a leukotriene receptor antagonist, in 6- to 14-year-old children with asthma.Eight-week, multicenter, randomized, double-blind study.Forty-seven outpatient centers at private practices and academic medical centers in the United States and Canada.A total of 336 children with forced expiratory volume in 1 second (FEV1) between 50% to 85% of the predicted value, at least 15% reversibility after inhaled beta-agonist administration, a minimal predefined

1998 JAMA